VZV is one of eight herpes viruses and commonly causes chickenpox in children, teens and herpes zoster (shingles) in adults. It is usually a mild disease that lasts a short time in healthy children. However, it can be severe in adults and may cause serious and even fatal complications in people of any age.

Read More

Have questions about a product?

Contact us to learn more about Meridian’s molecular or immunoassay reagent portfolio. We want to hear from you!

Contact A Specialist
Product Filters

Clear All

VZV Products (7)

Filters Close
Name Type Format Host/Source Isotype Tested Apps Unit Catalog SDS COA Request Sample
Varicella Zoster Virus II Ag Antigen Partially Purified HF Cells N/A EIA ML 7740 View SDS View COA Order A Sample
Varicella Zoster Virus antigen Antigen Partially Purified HF Cells N/A EIA,Pr ML 7209 View SDS View COA Order A Sample
Varicella Zoster Virus PBS Ag Antigen Partially Purified HF Cells N/A EIA ML 7201 View SDS View COA Order A Sample
VZV Ag, ORF9 (Dumas) Recomb Antigen Purified E. coli N/A EIA,WB MG R18401 View SDS View COA Order A Sample
VZV Ag, Ge(ellen) Recomb Antigen Purified E. coli N/A EIA,WB MG R18330 View SDS View COA Order A Sample
VZV Glycoprotein antigen Ellen Antigen Purified Human Embryo Lung Cell Culture N/A EIA MG R14041 View SDS View COA Order A Sample
MAb to VZV (mixed) Monoclonal Purified Mouse Mixed IFA,IHC,IP,WB,EIA MG C05108MA View SDS View COA Order A Sample

Varicella Zoster Virus (VZV)

VZV infects the nerves causing a wide variety of symptoms and two clinically distinct forms of disease. Primary infection results in chickenpox and recurrent infections leads to herpes zoster (shingles). Symptoms of VZV are exhibited between 10 and 21 days after infection. The main symptom is a rash that turns into open lesions which crust over. It is spread through the airborne route primarily from the skin vesicles. The immunologic mechanism that controls latency of VZV is not well understood, however factors associated with recurrent disease include aging, immunosuppression, intrauterine exposure to VZV, and having had varicella at a young age (younger than 18 months). Infection with VZV is generally mild and self-limited, but it may be associated with complications, especially in adults or children under 1-year old. Secondary bacterial infections of skin lesions with Staphylococcus or Streptococcus are the most common cause (5% of cases) of hospitalization and invasive group A streptococci can lead to serious illness or death. Other complications include secondary pneumonia (bacterial or viral), aseptic meningitis, encephalitis, myocarditis and arthritis. A rarer complication is Reye’s syndrome and occurs almost exclusively in children who take aspirin during the acute illness. Routine vaccination against VZV is performed in the United States and Japan, however most countries still do not vaccinate. It is now available as a quadrivalent measles-mumps-rubella-varicella (MMRV) vaccine and it is gaining wider acceptance globally. The VZV vaccine is on the World Health Organization’s (WHO) List of Essential Medicines, a list of the most important medications needed in a basic health system.

Congenital Infection

Primary maternal varicella infection in the first 20 weeks of gestation is associated with a variety of abnormalities in the newborn collectively known as congenital varicella syndrome. The range and severity of associated symptoms and physical findings may vary greatly from case to case depending upon when the maternal varicella zoster infection occurred during fetal development. In general, newborns with congenital VZV have a low birth weight, distinctive skin abnormalities, and brain malformations.


The clinical presentations of VZV are very characteristic, however diagnosis is important for determining the immune status before prognostic and therapeutic monitoring. Several methods exist including polymerase chain reaction (PCR), direct immunofluorescent assay (DFA), viral isolation and serologic assays that detect VZV-specific antibodies. Recent infection is suggested by the detection of serum VZV-specific IgM antibodies, but this can be less reliable for herpes zoster where specific antibodies are already present. The National VZV Laboratory at the CDC has developed a reliable IgM capture assay. Other current commercials assays for determining VZV immune status include ELISAs, latex agglutination, indirect-immunofluorescence assay (IFA) and enzyme-linked fluorescent immunoassay (ELFAs).

Get In Touch With A Specialist

Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!

By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.

Learn More About Us

Learn More
Welcome to
logo blue

Please select your country to continue